Antengene Corporation,Antengene Antengene Corporation,Antengene
  • Home
  • About Us
    About Antengene Management Team Board Of Directors Scientific Advisory Board Antengene Events Investors Company honor Contact Us
  • Our Business
    Discovery Development Manufacturing Commercialization Pipeline
  • Our Products
  • Newsroom
  • Partnerships
    Partnering with Antengene Partnership
  • Investor Relations
    Announcements & Circulars Corporate Governance Financial Report Webcast & Presentation Event Calendar Investor Contact
  • Career
    Social Responsibility Working at Antengene Join Us
简 EN
Treating Patients

Beyond Borders™

about antengene
Treating Patients

Beyond Borders™

about antengene
TRANSFORMING PATIENTS’ LIVES

By Discovering, Developing and Commercializing Global First-in-Class, Only-in-Class and/or Best-in-Class Therapies

mainMore GmainMore
Antengene Events
2017
2018
2019
2020
2021
2017
2018
2019
2020
2021
2017
2017

Our clinical research and development center was established and commenced operation in Shanghai

We and Celgene established cooperation to develop and commercialize ATG-008 (onatasertib) in the APAC region

Our Group completed the Series A financing with an aggregate amount of approximately US$21 million

2018
2018

IND approval for the TORCH trial with respect to ATG-008 (onatasertib) was received in Taiwan

We and Karyopharm established cooperation to develop and commercialize four clinical-stage drug candidates, including ATG-010 (selinexor), in mainland China and certain other Asian countries and regions

IND approvals for the TORCH trial with respect to ATG-008 (onatasertib) were received in mainland China and South Korea

ATG-008 was selected into National Science and Technology Major Project

2019
2019

IND approval for the MARCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our Group completed the Series B financing with an aggregate amount of approximately US$120 million

IND approval for the SEARCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our Regulatory Affairs Center commenced operation in Beijing

Our Group won the championship of the 8th China Innovation & Entrepreneurship Competition

We and AstraZeneca established cooperation to develop, manufacture and commercialize ATG-017 worldwide

IND approval for the TEACH trial with respect to ATG-019 was received in Taiwan

ATG-010 was selected into National Science and Technology Major Project

2020
2020

Antengene was successfully listed on The Stock Exchange of Hong Kong Limited

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor) in Mainland China for the Treatment of Myelodysplastic Syndrome

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

IND approval for the TOUCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our licensed rights under the license agreement with Karyopharm were expanded to 17 APAC countries and regions

Our Group completed the Series C financing with an aggregate amount of approximately US$97 million

IND approval for the BUNCH trial with respect to ATG-008 (onatasertib) was received in mainland China

IND approval for the ERASER trial with respect to ATG-017 was received in Australia

Our Drug Discovery Center commenced operation in Shanghai

Our Manufacturing Center commenced operation in Zhejiang Province

2021
2021

Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China’s NMPA

Antengene Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

Antengene Included in the Shenzhen-Hong Kong Stock Connect

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma

2017
2017

Our clinical research and development center was established and commenced operation in Shanghai

We and Celgene established cooperation to develop and commercialize ATG-008 (onatasertib) in the APAC region

Our Group completed the Series A financing with an aggregate amount of approximately US$21 million

2018
2018

IND approval for the TORCH trial with respect to ATG-008 (onatasertib) was received in Taiwan

We and Karyopharm established cooperation to develop and commercialize four clinical-stage drug candidates, including ATG-010 (selinexor), in mainland China and certain other Asian countries and regions

IND approvals for the TORCH trial with respect to ATG-008 (onatasertib) were received in mainland China and South Korea

ATG-008 was selected into National Science and Technology Major Project

2019
2019

IND approval for the MARCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our Group completed the Series B financing with an aggregate amount of approximately US$120 million

IND approval for the SEARCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our Regulatory Affairs Center commenced operation in Beijing

Our Group won the championship of the 8th China Innovation & Entrepreneurship Competition

We and AstraZeneca established cooperation to develop, manufacture and commercialize ATG-017 worldwide

IND approval for the TEACH trial with respect to ATG-019 was received in Taiwan

ATG-010 was selected into National Science and Technology Major Project

2020
2020

Antengene was successfully listed on The Stock Exchange of Hong Kong Limited

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor) in Mainland China for the Treatment of Myelodysplastic Syndrome

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

IND approval for the TOUCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our licensed rights under the license agreement with Karyopharm were expanded to 17 APAC countries and regions

Our Group completed the Series C financing with an aggregate amount of approximately US$97 million

IND approval for the BUNCH trial with respect to ATG-008 (onatasertib) was received in mainland China

IND approval for the ERASER trial with respect to ATG-017 was received in Australia

Our Drug Discovery Center commenced operation in Shanghai

Our Manufacturing Center commenced operation in Zhejiang Province

2021
2021

Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China’s NMPA

Antengene Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

Antengene Included in the Shenzhen-Hong Kong Stock Connect

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma

LATEST NEWS
view more
May 23, 22
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
view more
May 18, 22
Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
view more
May 14, 22
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China
view more
May 14, 22
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress
view more
  • Home
  • About us
  • Our Business
  • Newsroom
  • Partnerships
  • investor Relations
  • career

Copyright © 2020 By Antengene Corporation. All Rights Reserved sitemap sitemap

  • About Us
    About Us Management Team Board Of Directors Scientific Advisory Board antengene events Investors Company honor Contact Us
  • Our Business
    Discovery Development Manufacturing Commercialization Pipeline
  • Newsroom
  • Partnerships
    Partnering with Antengene Partnership
  • Investor Relations
    Announcements & Circulars Corporate Governance Financial Report Corporate Presentation Event Calendar Investor Contact
  • Career
    Social Responsibility Working at Antengene Join Us